ADMS - アダマス・ファ―マシュ―ティカルズ (Adamas Pharmaceuticals Inc.) アダマス・ファ―マシュ―ティカルズ

 ADMSのチャート


 ADMSの企業情報

symbol ADMS
会社名 Adamas Pharmaceuticals Inc (アダマス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アダマス・ファーマシューティカル(Adamas Pharmaceuticals Inc)は製薬会社である。同社は慢性神経障害の罹患者の日常生活を管理するための医薬品の開発に従事する。同社は耐性の問題なしで救済を達成するために、疾患活動および薬物応答の時間依存性生物学的影響の理解に基づくプラットフォームを提供する。同社は慢性神経障害に対処するためのクロノ同期療法のポートフォリオを開発した。最初の製品候補は、パーキンソン病(PD)患者のレボドパ誘発ジスキネジー(LID)の治療のための、クロモ同期型アマンタジン療法であるADS-5102である。これらの患者におけるADS-5102の第Ⅱ相実証試験を完了した。同社の第III相臨床プログラムには、EASED、EASE LIDおよびEASE LID 3の3つのプラセボ対照試験が含まれる。同社の2番目の製品候補は、てんかん(部分発作)の治療用単剤化合物の延長放出型であるADS-4101である。   アダマス・ファ―マシュ―ティカルズは米国の特殊製薬会社。アルツハイマ―病、パ―キンソン病、TBI(全身被ばく)、てんかん、精神病、うつ病などの中枢神経系の慢性疾患、及び被ばく者のための治療法の開発、商業化に従事。承認薬の薬物動態プロファイルを強化することで、一人で使用できる多剤混合薬の新規治療薬を作ることを実現。本社はカリフォルニア州。   Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
本社所在地 1900 Powell Street Suite 750 Emeryville CA 94608 USA
代表者氏名 Gregory T. Went グレゴリーT.ウェント
代表者役職名 Chairman of the Board Chief Executive Officer Co-Founder
電話番号 +1 510-450-3554
設立年月日 36831
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 147人
url www.adamaspharma.com
nasdaq_url https://www.nasdaq.com/symbol/adms
adr_tso
EBITDA EBITDA(百万ドル) -111.08500
終値(lastsale) 17.44
時価総額(marketcap) 474201500.32
時価総額 時価総額(百万ドル) 475.56100
売上高 売上高(百万ドル) 10.68700
企業価値(EV) 企業価値(EV)(百万ドル) 383.86000
当期純利益 当期純利益(百万ドル) -121.68100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adamas Pharmaceuticals Inc revenues increased from $2K to $10.1M. Net loss increased 88% to $69M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other General and Administrative. increase from $17.3M to $47.7M (expense) Interest expense increase from $729K to $9.9M (expense).

 ADMSのテクニカル分析


 ADMSのニュース

   ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action  2020/02/05 20:00:00 PR Newswire
NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30, 2019, inclusive (the "Class Period"), of the important February 10, 2020 lead plaintiff…
   ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.  2020/02/03 15:11:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of
   GE T&D bags Rs 173 cr JKPDD contract  2020/01/23 11:17:15 The Economic Times India
GE T&D India on Thursday said it bagged a Supervisory Control and Data Acquisition (SCADA) and Advanced Distribution Management Solution (ADMS) project by the Jammu & Kashmir Power Development Department (JKPDD) worth Rs 173 crore for distribution operations in the cities of Jammu and Srinagar.The order won through a competitive bidding process includes a 5-year maintenance services contract and supply and integration of a host of solutions in the overall distribution network in the two cities, an official statement said.The technology solution being executed for this project is used mainly for 24x7 power supply, reduction of power losses and real-time data monitoring and control of distribution network from a centralised place.This will determine the setting up of reliable systems for system control/data collection and adoption of Information Technology in the area of energy accounting.SCADA technology reduces aggregate technical and commercial (AT&C) losses and enables real-time monitoring and control of the electric distribution network, handling of loads during load shedding and restoration and plugging of pilferage points, it said.
   ADMS ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS  2020/01/04 16:01:01 MarketScreener
NEW YORK, Jan. 04, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30,…
   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.  2019/12/20 17:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
   ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action  2020/02/05 20:00:00 PR Newswire
NEW YORK, Feb. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30, 2019, inclusive (the "Class Period"), of the important February 10, 2020 lead plaintiff…
   ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.  2020/02/03 15:11:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of
   GE T&D bags Rs 173 cr JKPDD contract  2020/01/23 11:17:15 The Economic Times India
GE T&D India on Thursday said it bagged a Supervisory Control and Data Acquisition (SCADA) and Advanced Distribution Management Solution (ADMS) project by the Jammu & Kashmir Power Development Department (JKPDD) worth Rs 173 crore for distribution operations in the cities of Jammu and Srinagar.The order won through a competitive bidding process includes a 5-year maintenance services contract and supply and integration of a host of solutions in the overall distribution network in the two cities, an official statement said.The technology solution being executed for this project is used mainly for 24x7 power supply, reduction of power losses and real-time data monitoring and control of distribution network from a centralised place.This will determine the setting up of reliable systems for system control/data collection and adoption of Information Technology in the area of energy accounting.SCADA technology reduces aggregate technical and commercial (AT&C) losses and enables real-time monitoring and control of the electric distribution network, handling of loads during load shedding and restoration and plugging of pilferage points, it said.
   ADMS ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS  2020/01/04 16:01:01 MarketScreener
NEW YORK, Jan. 04, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30,…
   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.  2019/12/20 17:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
   ADMS ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS  2020/01/04 16:01:01 MarketScreener
NEW YORK, Jan. 04, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. between August 8, 2017 and September 30,…
   Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.  2019/12/20 17:00:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADMS--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm  2019/12/17 23:18:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ADMS #ADMS--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc.
   Adamas drug to help MS patients walk does not show expected clinical benefit  2019/12/17 14:11:44 Channel NewsAsia
REUTERS: Adamas Pharmaceuticals Inc said on Tuesday its drug to treat walking impairment in patients with multiple sclerosis did not show the …
   Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy ?  2019/12/16 10:45:55 Yahoo Finance
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Adamas Pharmaceuticals Inc (NASDAQ:ADMS). Is Adamas Pharmaceuticals

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アダマス・ファ―マシュ―ティカルズ ADMS Adamas Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)